Consortium invests $30m in series-B round for Eyevensys
Boehringer Ingelheim Venture Fund has led a $30m series-B round for France-based Eyevensys, a clinical-stage biotechnology company developing non-viral gene therapies for retinal and other ophthalmic diseases.
More on Expansion
Capza acquires minority stake in Nutravalia
French food supplements laboratory to seek opportunistic strategic acquisitions
EcoVadis valued at over USD 1bn in Astorg, BeyondNetZero-led round
Deal brings total raised by sustainability rating group to USD 725m; CVC remains largest institutional shareholder
Inflexion reinvests in Apax-backed Alcumus
Inflexion originally sold the risk management business in February via a GBP 600m SBO to Apax
VC Profile: Jeito Capital in final stretch of biotech fund deployment
Founder Rafaèle Tordjman outlines the French sponsor’s strategy as it aims to remain independent amid wave of consolidation in healthcare funds
Latest News
Secondaries GPs expect record 2022 – Investec
Fifth Secondaries Market Report also reveals that 97% of secondaries investors are participating in GP-leds
Eurazeo in exclusivity for Sevetys acquisition
French sponsor beats Ardian and Antin in race for a majority stake in French veterinary chain
VC Profile: Octopus backs pre-seed ecocystem with fresh fund
Fund is headed by Kirsten Connell and Maria Rotilu and has extended its hard cap to GBP 15m following a first close
Bowmark backs Cornwall Insight buyout
BGF exits energy markets consultancy following minority stake investment in 2017